Ross Camidge, MD, PhD

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the ever changing and evolving world of clinical cancer research.

Dr. Ross Camidge, from the University of Colorado Cancer Center, Discusses Resequencing Lung Cancer